Prime Medicine, Inc. (PRME)

USD 1.74

(24.82%)

Market Cap (In USD)

227.56 Million

Revenue (In USD)

-

Net Income (In USD)

-198.13 Million

Avg. Volume

1.33 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.6-9.8
PE
-1.05
EPS
-1.65
Beta Value
2.093
ISIN
US74168J1016
CUSIP
74168J101
CIK
1894562
Shares
131160840.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Keith Michael Gottesdiener M.D., Ph.D.
Employee Count
-
Website
https://www.primemedicine.com
Ipo Date
2022-10-20
Details
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.